Seminars in Oncology
Volume 29, Issue 3 , Pages 274-279 , June 2002

Pathological and molecular assessment of sentinel lymph nodes in solid tumors

References 

  1. Saphir O, Amromin G. Obscure axillary lymph-node metastasis in carcinoma of the breast. Cancer. 1948;1:238–241
  2. Heller R, Becker J, Wasselle J, et al.  Detection of submicroscopic lymph node metastases in patients with melanoma. Arch Surg. 1991;126:1455–1460
  3. Balch CM, Buzaid AC, Soong SJ, et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648
  4. Cochran AJ, Wen DR, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study. Am J Surg Pathol. 1988;12:612–618
  5. Vaggelli L, Castagnoli A, Borgognoni B, et al.  Radioisotopic lymphatic mapping of the sentinel node in melanoma: Importance of immunohistochemistry. Tumori. 2000;86:346–348
  6. Yu LL, Fiotte TJ, Tanabe KK, et al.  Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer. 1999;86:617–627
  7. Baisden BL, Askin FB, Lange JR, et al.  HMB-45 immunohistochemical staining of sentinel lymph nodes: A specific method for enhancing detection of micrometastases in patients with melanoma. Am J Surg Pathol. 2000;24:1140–1146
  8. Messina JL, Glass LF, Cruse CW, et al.  Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol. 1999;23:686–690
  9. Shivers SC, Wang X, Li W, et al.  Molecular staging of malignant melanoma: Correlation with clinical outcome. JAMA. 1998;280:1410–1415
  10. Blaheta HJ, Ellwanger U, Schittek B, et al.  Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol. 2000;114:637–642
  11. Goydos JS, Ravikumar TS, Germino FJ, et al.  Minimally invasive staging of patients with melanoma: Sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. J Am Coll Surg. 1998;187:182–190
  12. Bieligk SC, Ghossein R, Bhattacharya S, et al.  Detection of tyrosinase mRNA by reverse transcription-polymerase chain reaction in melanoma sentinel nodes. Ann Surg Oncol. 1999;6:232–240
  13. Palmieri G, Ascierto PA, Cossu A, et al.  Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay. J Clin Oncol. 2001;19:1437–1443
  14. van der Velde-Zimmermann D, Schipper ME, de Weger RA, et al.  Sentinel node biopsies in melanoma patients: A protocol for accurate, efficient, and cost-effective analysis by preselection for immunohistochemistry on the basis of Tyr-PCR. Ann Surg Oncol. 2000;7:51–54
  15. Blaheta HJ, Schittek B, Breuninger H, et al.  Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. Am J Surg Pathol. 1999;23:822–828
  16. Cascinelli N, Belli F, Santinami M, et al.  Sentinel lymph node biopsy in cutaneous melanoma: The WHO Melanoma Program experience. Ann Surg Oncol. 2000;7:469–474
  17. Gershenwald JE, Colome MJ, Lee JE, et al.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253–2260
  18. Harlow SP, Krag DN, Ashikaga T, et al.  Gamma probe guided biopsy of the sentinel node in malignant melanoma: A multicentre study. Melanoma Res. 2001;11:45–55
  19. Landi G, Polverelli M, Moscatelli G, et al.  Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases. J Eur Acad Dermatol Venereol. 2000;14:35–45
  20. Muller MG, Borgstein PJ, Pijpers R, et al.  Reliability of the sentinel node procedure in melanoma patients: Analysis of failures after long-term follow-up. Ann Surg Oncol. 2000;7:461–468
  21. Fitzgibbons PL, Page DL, Weaver D, et al.  Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966–978
  22. van Diest PJ, Peterse HL, Borgstein PJ, et al.  Pathological investigation of sentinel lymph nodes. Eur J Nucl Med. 1999;26(suppl 4):S43–S49
  23. Liberman L. Pathologic analysis of sentinel lymph nodes in breast carcinoma. Cancer. 2000;88:971–977
  24. Czerniecki BJ, Scheff AM, Callans LS, et al.  Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer. 1999;85:1098–1103
  25. Dowlatshahi K, Fan M, Anderson JM, et al.  Occult metastases in sentinel nodes of 200 patients with operable breast cancer. Ann Surg Oncol. 2001;8:675–681
  26. Schreiber RH, Pendas S, Ku NN, et al.  Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node. Ann Surg Oncol. 1999;6:95–101
  27. Weaver DL, Krag DN, Ashikaga I, et al.  Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: A multicenter study. Cancer. 2000;88:1099–1107
  28. Turner RR, Ollila DW, Krasne DL, et al.  Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg. 1997;226:271–278
  29. Nahrig J, Richter T, Kowolik J, et al.  Comparison of different histopathological methods for the examination of sentinel lymph nodes in breast cancer. Anticancer Res. 2000;20:2209–2212
  30. Bostick PJ, Huynh KT, Sarantou T, et al.  Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple-marker RT-PCR. Int J Cancer. 1998;79:645–651
  31. Neumaier M, Gerhard M, Wagener C. Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene. 1995;159:43–47
  32. Bostick PJ, Chatterjee S, Chi DD, et al.  Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol. 1998;16:2632–2640
  33. Manzotti M, Dell'Orto P, Maisonneuve P, et al.  Reverse transcription-polymerase chain reaction assay for multiple mRNA markers in the detection of breast cancer metastases in sentinel lymph nodes. Int J Cancer. 2001;95:307–312
  34. Turner RR, Chu KU, Qi K, et al.  Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000;89:574–581
  35. Klauber-DeMore N, Tan LK, Liberman L, et al.  Sentinel lymph node biopsy: Is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion?. Ann Surg Oncol. 2000;7:636–642
  36. Pendas S, Dauway R, Giuliano R, et al.  Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol. 2000;7:15–20
  37. Harlow SP, Krag DN. Sentinel lymph node-why study it: Implications of the B-32 study. Semin Surg Oncol. 2001;20:224–229

☆ Address reprint requests to David Krag, MD, University of Vermont, College of Medicine, Given Bldg, Room E309, Burlington, VT 05405.

PII: S0093-7754(02)50183-4

doi: 10.1053/sonc.2002.32894

Seminars in Oncology
Volume 29, Issue 3 , Pages 274-279 , June 2002

Article Tools